Medigene, GC-Rise deal

MediGene granted GC-Rise rights to commercialize Veregen polyphenon E in China. GC-Rise is responsible for clinical trials and regulatory approval of Veregen, and expects to launch the product by the end of 2013. MediGene will receive an upfront payment and is eligible to receive a milestone payment upon the start of a clinical trial. Specific financial details were not disclosed. ...